Document is current
Any future updates will be listed below
-
Authors
Ellingsen, Espen Basmo https://orcid.org/0000-0002-0235-1184
Aamdal, Elin
Guren, Tormod
Lilleby, Wolfgang
Brunsvig, Paal F
Mangsbo, Sara M
Aamdal, Steinar
Hovig, Eivind
Mensali, Nadia
Gaudernack, Gustav
Inderberg, Else Marit
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02275416 at ClinicalTrials.govnct01789099 at ClinicalTrials.govDocuments that mention this clinical trial
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
https://doi.org/10.1136/jitc-2021-004345
382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.382
nct01784913 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
https://doi.org/10.1136/jitc-2021-004345
nct04742075 at ClinicalTrials.govDocuments that mention this clinical trial
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
https://doi.org/10.1136/jitc-2021-004345
nct04382664 at ClinicalTrials.govDocuments that mention this clinical trial
A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps5615
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
https://doi.org/10.1136/jitc-2021-004345
2022-RA-1267-ESGO A randomised clinical Trial Investigating olaparib, durvalumab and an anticancer vaccine, UV1 as maintenance therapy in patients with recurrent ovarian cancer. ENGOT-OV56-NSGO-CTU-DOVACC
https://doi.org/10.1136/ijgc-2022-esgo.671
nct04300244 at ClinicalTrials.govDocuments that mention this clinical trial
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
https://doi.org/10.1136/jitc-2021-004345
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9519
Documents that mention this clinical trial
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
https://doi.org/10.1136/jitc-2021-004345
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
https://doi.org/10.1186/s12967-021-02905-3
- License Information
